Latest Articles
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer - BioSpace
Merck’s billion-dollar Kelun bet pays off as TROP2 improves survival in endometrial cancer BioSpace
Published: May 19, 2026, 11:19 a.m.
Merck-Kelun ADC boosts survival in phase 3 endometrial cancer, stokes TROP2 race - CHOSUNBIZ - Chosunbiz
Merck-Kelun ADC boosts survival in phase 3 endometrial cancer, stokes TROP2 race - CHOSUNBIZ Chosunbiz
Published: May 19, 2026, 6:54 a.m.
Merck’s TROP2 ADC opens global women’s cancer push with endometrial win - BioCentury
Merck’s TROP2 ADC opens global women’s cancer push with endometrial win BioCentury
Published: May 18, 2026, 10:04 p.m.
Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress - The Manila Times
Kelun-Biotech Presented TROP2 ADC Sacituzumab Tirumotecan Results From Multiple Clinical Studies at the 2025 CCHIO Congress The Manila Times
Published: Nov. 10, 2025, 2:19 a.m.
ASCENT-Gyn-01 Trial of Sacituzumab Govitecan Aims to Validate Clinical Utility of TROP2 ADCs in Pretreated Endometrial Cancer - OncLive
ASCENT-Gyn-01 Trial of Sacituzumab Govitecan Aims to Validate Clinical Utility of TROP2 ADCs in Pretreated Endometrial Cancer OncLive
Published: Sept. 26, 2025, 7:40 p.m.
Immunohistochemical examination of CD163 and TROP2 expression levels in ovarian endometriosis.
Published: Aug. 22, 2025, midnight
Link copied to clipboard!